A new prognostic tool can help predict outcomes of a novel targeted therapy in men with metastatic castration-resistant prostate cancer (mCRPC). The tool, described in a paper published in July 2021 in The Lancet Oncology, combines imaging and clinical data to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen (Lu-PSMA)—a novel targeted treatment for the disease.
To develop the tool, researchers screened 270 mCRPC patients who had received Lu-PSMA in previous clinical trials or via compassionate use. They used parameters like time since initial diagnosis, chemotherapy status, hemoglobin levels, and PSMA PET imaging characteristics to create a mathematical formula that estimates the risk of overall and progression-free survival for patients treated with Lu-PSMA and stratifies patients into either high-risk or low-risk groups.
According to the paper, patients identified by the tool as low risk had longer overall and progression-free survival than those classified as high risk. The researchers also created an online risk calculatorthat forecasts the probability of overall and progression-free survival in response to Lu-PSMA.
They conclude that the tool and online risk calculator can assist in clinical trial design and clinical decision making, but still require further validation via prospective clinical trials.